Related Experiment Video
Updated: Oct 27, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Oncogenic activity and cellular functionality of melanoma associated antigen A3
Paula Schäfer1, Themistoklis Paraschiakos1, Sabine Windhorst1
1Department of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Melanoma associated antigen A3 (MAGE-A3) is a promising cancer target due to its tumor-specific expression. Despite early trial success, MAGE-A3 immunotherapies require further optimization for clinical efficacy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Melanoma associated antigen A3 (MAGE-A3) is a cancer-testis antigen expressed in various tumors but not healthy tissues, making it a potential therapeutic target.
- MAGE-A3 regulates cellular processes including proliferation and metastasis by interacting with TRIM28, affecting tumor suppressor p53 and AMPK.
- Previous MAGE-A3-targeted immunotherapies showed promise in early clinical trials but failed in later stages.
Purpose of the Study:
- To provide an overview of MAGE-A3's function as a cellular master regulator.
- To discuss the potential of MAGE-A3 as a target for cancer vaccines.
- To explore strategies for enhancing the efficacy of MAGE-A3-based immunotherapies.
Main Methods:
- Review of existing literature on MAGE-A3 function and clinical trial data.
- Analysis of MAGE-A3's role in regulating key cellular pathways (e.g., p53, AMPK) via TRIM28.
- Exploration of mechanisms underlying the success and failure of MAGE-A3 immunotherapies.
Main Results:
- MAGE-A3 acts as a master regulator, influencing tumor growth and spread.
- Restricted MAGE-A3 expression supports its use in targeted cancer vaccines.
- Phase III trial failures highlight challenges in MAGE-A3 immunotherapy efficacy.
Conclusions:
- MAGE-A3 remains a compelling target for cancer immunotherapy due to its unique expression profile.
- Further research is needed to overcome the limitations observed in MAGE-A3-based therapies.
- Optimizing MAGE-A3 immunotherapeutic strategies is crucial for clinical success.
More Related Videos
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Induced Pluripotent Stem Cells
Somatic...
Mutagenicity and Carcinogenicity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...